MXL– MaxLinear, Inc provides integrated, radio-frequency (RF) mixed-signal integrated circuits for broadband communications and data center and other network applications.
MXL – MaxLinear, Inc
|Fundamentals||Previously closed at||18.54|
|Analysts opinion||The business it is in, as a producer of Radio Frequency and mixed-signal circuits has a huge potential, with the trend of consumers’ demand for higher quality video streaming, and increased content online. MXL gained 10.9% in the last four weeks. It is expected to grow (EPS) at an exceptional 45.2%. The sell-side analysts have a 1.14 rating for the stock indicating a “Strong Buy”. Deere & Co boosted its stake in MXL by 0.7%, California State Teachers Retirement System increased its stake by 1.7%, American Century companies Inc., AlphaMark Advisors LLC and Numeric Investors LLC etc. acquired new stakes in MXL last quarter.|
|Technically, MXL is supposedly forming a second stage cup with handle base. It has support/resistance levels at $18.50 and $13.77. Insider Curtis Ling, the Chief Technical Officer sold 36,800 shares of the company on Tuesday at an average price of $18.02.|
|Sentiments||Due to the news, the investor sentiments may be bullish for the stock.|
|Revenue Prediction||Analysts are expecting the revenue to grow at 42% this next quarter and 32% for the year.|
|Social Media Pulse||The stock has 55% higher chatter than usual.|
CELG – Celgene Corporation, is a bio-pharmaceutical company, engaged in development and commercialization of therapies for treatment of cancer and inflammatory diseases through gene and protein regulation.
CELG – Celgene Corporation
|Fundamentals||Previously closed at||108.22|
|Analyst opinion||Analysts have a consensus 1.44 rating for the stock, which suggest a “Strong Buy”. The consensus target price for the stock is $145.84. The company has strong growth prospects.|
|Sentiments||Sentiments for the stock are bullish, post termination of merger of Pfizer and Allergan. There has been a lot of speculation regarding the subject, and given the fact that Allergan and Pfizer have been serial acquirers in healthcare, now that the merger is terminated it opens up a huge space for potential acquisitions. Investors are bullish on CELG due to it being a possible acquisition target for Allergan.|
|Social Media Pulse||The stock has 100% higher social chatter than usual.|
Disclaimer: This blog contains an aggregated view of analysts and opinions by the author. Do not consider this as financial advice. See http://stockal.com/legalities/